Muscle Wasting
Conditions
Keywords
Critical Illness, Trauma, Fatty Acids, Anthropometry, Nutrition Disorders, Sarcopenia
Brief summary
The risk of muscle wasting, and sarcopenia is high in the intensive care unit patients and associated with adverse clinical outcomes. The etiology of muscle wasting is multifactorial and medical nutrition therapy plays a key role in treatment and prevention. The purpose of this study is to evaluate the effect of omega-3 fatty acids in the treatment and/or prevention of muscle wasting in critically ill trauma patients.
Detailed description
Low skeletal muscle mass and loss of lean tissue in critically illness have been associated with negative clinical outcomes. Critically ill patients may lose about 25% of their skeletal muscle mass within 7 days of admission to the intensive care unit. Besides increased protein catabolism, other factors inherent to the ICU environment contribute to muscle loss, including patient immobility and interruptions in nutrient delivery. This combination of factors is especially debilitating in patients with preexisting low muscle stores due to sarcopenia, chronic illness, or malnutrition. Although preservation of skeletal muscle mass is important for recovery in critically ill patients, the mechanism of muscle wasting is not unknown. Muscle wasting is a multifactorial process and it may be the consequence of several events, including oxidative stress, inflammatory conditions and muscle remodeling. Omega-3 fatty acids with their anti-inflammatory, antioxidant and anabolic effects can be a key factor for an effective treatment.
Interventions
DIETARY_SUPPLEMENTomega 3 fatty acid
Participants will take 0.1-0.2 g/kg/day of omega 3 fatty acids for 7 days.
Sponsors
Karadeniz Technical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Age ≥18 years and ≤80 years, Expected ICU stay of seven days or longer Written informed consent or requirements of local/national ethical committee
Exclusion criteria
Pregnancy or breastfeeding Neuromuscular conditions (e.g., multiple sclerosis, muscular dystrophy, spinal cord injury, Guillain-Barre syndrome) Current cancer or chemotherapy End-stage of renal failure or dialysis treatment or renal transplantation prior to ICU admission Burn injury History of transplantation Pretibial edema Uncontrolled hemorrhage Uncontrolled hyperlipidemia Acute pancreatitis Acute thromboembolic diseases Severe heart failure Septic shock Concurrent enrolment in a nutrition-related interventional study at the time of screening
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in rectus femoris muscle cross-sectional area | Baseline and 7 days | Will be evaluated by ultrasound. |
| Changes in mid-upper arm and calf circumferences | Baseline and 7 days | Will be measured by tape measure. |
| Changes in triceps and biceps skinfold thickness Changes in triceps and biceps skinfold thickness | Baseline and 7 days | Will be measured by caliper. |
| Changes in biochemical parameters related to muscle homeostasis, oxidative stress and inflammation | Baseline and 7 days | Biochemical parameters related to muscle wasting such as TNF-a, IL-6, TOS, P3NP |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hospital Length of Stay | Time of discharge from the ICU until hospital discharge, up to 1 year | Time from study inclusion to hospital discharge. |
| 28-day mortality | 28 day | Mortality rate |
| Intensive care unit length of stay | Time of admission to the ICU until the time of discharge from the intensive care unit, up to 1 year | Time from study inclusion to intensive care unit discharge. |
Countries
Turkey (Türkiye)
Outcome results
None listed